Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
19 hedge funds and large institutions have $1.08M invested in Baudax Bio, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 19 → 19 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
51% less capital invested
Capital invested by funds: $2.2M → $1.08M (-$1.12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$228K |
| 2 |
Renaissance Technologies
New York
|
+$96.9K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$33K |
| 4 |
HF
HRT Financial
New York
|
+$27.3K |
| 5 |
VF
Virtu Financial
New York
|
+$24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$416K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$78.3K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$23K |
| 4 |
Jane Street
New York
|
-$19K |
| 5 |
BlackRock
New York
|
-$8.65K |
BXRX Hedge Fund Activity: Q2 2022 in Review
19 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q2 2022, worth a combined $1.08M — down 51% from $2.2M a quarter earlier.
Fund positioning in BXRX was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Walleye Capital, opening a new position worth an estimated $228K. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $416K sold.
- 19 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.08M of Baudax Bio, Inc. Common Stock stock for Q2 2022, down 51% quarter-over-quarter.
- 5 funds opened new Baudax Bio, Inc. Common Stock positions in Q2 2022 and 5 closed out, a net change of 0 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q2 2022 was Walleye Capital, an estimated $228K added.
- The largest Baudax Bio, Inc. Common Stock seller in Q2 2022 was D.E. Shaw & Co, an estimated $416K sold.
Based on aggregated 13F filings for Q2 2022.